Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16487204 | 0.90 | SLC6A2 (0.44) | TSHRLMNATYRALDH1A1NR1H4 | |
| SCHEMBL25380412 | 0.88 | LMNA (0.73) | TSHRLMNATYRALDH1A1HPGD | |
| SCHEMBL22402545 | 0.88 | TRPV1 (0.46) | TSHRLMNATYRGRIA4KIF11 | |
| SCHEMBL13523895 | 0.88 | RAB9A (0.57) | TSHRLMNATYRGRIA4KIF11 | |
| SCHEMBL18175849 | 0.82 | KIF11 (0.45) | TSHRLMNATYRGRIA4KIF11 | |
| SCHEMBL424728 | 0.80 | TSHR (0.73) | TSHRLMNATYRKIF11ALDH1A1 | |
| SCHEMBL548066 | 0.80 | TSHR (0.50) | TSHRLMNATYRGRIA4KIF11 | |
| SCHEMBL9621026 | 0.80 | TSHR (0.50) | TSHRLMNATYRGRIA4KIF11 | |
| SCHEMBL8986298 | 0.79 | TSHR (0.35) | TSHRLMNATYRGRIA4KIF11 | |
| SCHEMBL18892919 | 0.78 | CYP1A2 (0.44) | TSHRLMNAALDH1A1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| US-7232634-B2 | Charge generating layer and a charge transport layer with bulky organic groups to prevent recrystallization of the charge transport molecule and shield the nitrogen from molecular attack; oxidation reisitance, wear resistance | XEROX CORPORATION (US) | 2007-06-19 | — | — | US | claimed |
| EP-0906329-B1 | 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-08 | — | — | EP | claimed |
| EP-0906329-A2 | 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES | Novartis AG (CH) | 1999-04-07 | — | — | EP | claimed |
| WO-1997046569-A2 | 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | claimed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| WO-2024074604-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | INSTITUTO BIOMAR, S.A (ES) | 2024-04-11 | — | — | WO | disclosed |
| EP-4349409-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | Instituto Biomar S.A. (ES) | 2024-04-10 | — | — | EP | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| EP-3615544-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-4101855-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| US-20060068309-A1 | Imaging member | XEROX CORPORATION | 2006-03-30 | — | — | US | disclosed |
| EP-0906329-B1 | 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| EP-0906329-A2 | 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES | Novartis AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| WO-1998056905-A1 | OLIGONUCLEOTIDE DERIVATIVES | NOVARTIS AG (CH) | 1998-12-17 | — | — | WO | disclosed |
| WO-1997046569-A2 | 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| US-5639867-A | TTTr as protective group in nucleotide synthesis | CIBA GEIGY CORPORATION (US) | 1997-06-17 | — | — | US | disclosed |
| US-5268464-A | Process for the preparation of nucleosides | CIBA-GEIGY CORPORATION (US) | 1993-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | TSHR 1530/4885LMNA 1254/4885TYR 428/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | TSHR 4670/4885LMNA 1898/4885TYR 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.